Fremont, CA, United States
Fremont, CA, United States

Time filter

Source Type

Chua B.,ArKal Medical Inc | Chua B.,Korea University | Desai S.P.,ArKal Medical Inc | Desai S.P.,Alexza Pharmaceuticals Inc. | And 4 more authors.
Sensors and Actuators, A: Physical | Year: 2013

The effect of microneedle shape on skin penetration and minimally invasive continuous glucose monitoring (CGM) was successfully investigated. Straight silicon microneedle arrays (SSMA) and tapered silicon microneedle arrays (TSMA) were fabricated using standard silicon micromachining techniques. Microneedle heights were ∼325 μm and ∼350 μm and pitch was 400 μm and 450 μm, respectively. Mode-I planar crack and mode-II ring crack propagation were assumed for TSMA and SSMA penetration mechanisms, respectively. Skin penetration was first qualitatively evaluated via methylene blue staining. TSMA and SSMA were also mounted on CGM system prototypes and applied on human subjects with an impact velocity of 10 m/s and worn for 6.5 h. The hollow microneedles allowed the glucose from the interstitial fluid in the epidermis to diffuse into the sensor chamber of the CGM system prototype. Sensor currents from the applied CGM system prototypes ranged from 100 nA to 400 nA and they appeared to follow the trend of the reference blood glucose sensor that ranged from ∼90 to 220 mg/dL. The CGM system prototype with SSMA yielded lower sensor current than that with TSMA. This may be due to the SSMA preferential penetration of skin via mode-II ring crack propagation, resulting in possible lumen occlusion from displaced skin material. © 2013 Elsevier B.V. All rights reserved.


Patent
Arkal Medical Inc. | Date: 2012-10-24

An analyte monitor having a plurality of fluid paths, each fluid path having a distal opening adapted to be disposed on one side of a stratum corneum layer of a users skin, a proximal opening adapted to be disposed on another side of the stratum corneum layer and an interior space extending between the distal and proximal openings; a sensing zone in fluid communication with the proximal openings of the fluid paths; sensing fluid extending from the sensing zone into substantially the entire interior space of the fluid paths; and an analyte sensor adapted to detect a concentration of analyte in the sensing fluid within the sensing zone, wherein at least one of the sensing fluid and the analyte sensor comprises a catalyst for mutarotation of glucose. The invention also includes a method of using the monitor.


Trademark
Arkal Medical Inc. | Date: 2011-08-19

devices for measuring blood sugar; medical test kits for diabetes monitoring for home use.


Trademark
Arkal Medical Inc. | Date: 2011-12-02

devices for measuring blood sugar; medical test kits for diabetes monitoring for home use.


Trademark
Arkal Medical Inc. | Date: 2011-08-19

devices for measuring blood sugar; medical test kits for diabetes monitoring for home use.


Trademark
Arkal Medical Inc. | Date: 2010-04-08

apparatus for analysis of glucose in biological fluids; apparatus for glucose monitoring; medical test kits for diabetes monitoring for home use; medical devices for the management and treatment of diabetes.


Trademark
Arkal Medical Inc. | Date: 2011-08-19

devices for measuring blood sugar; medical test kits for diabetes monitoring for home use.


Trademark
Arkal Medical Inc. | Date: 2011-08-19

devices for measuring blood sugar; medical test kits for diabetes monitoring for home use.


Trademark
Arkal Medical Inc. | Date: 2010-04-22

Devices for measuring blood sugar; Medical test kits for diabetes monitoring for home use.


Trademark
Arkal Medical Inc. | Date: 2010-04-20

Devices for measuring blood sugar; Medical test kits for diabetes monitoring for home use.

Loading ArKal Medical Inc. collaborators
Loading ArKal Medical Inc. collaborators